Details of the Drug Combination

General Information of Drug Combination (ID: DCMUTEJ)

• Drug Combination Name: BHV-0223 + Enoxacin
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  BHV-0223 (DMBLM5H): N.A.
  Enoxacin (DMYTE6L): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 5.2
  Bliss Independence Score: 5.2
  Loewe Additivity Score: 19.49
  LHighest Single Agent (HSA) Score: 19.51

Molecular Interaction Atlas of This Drug Combination

Indication(s) of BHV-0223

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[2]

Indication(s) of Enoxacin

Disease Entry	ICD 11	Status	REF
Acute gonococcal cervicitis	N.A.	Approved	[3]
Urinary tract infection	GC08	Approved	[4]

Enoxacin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[5]

Enoxacin Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[6]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[7]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Enoxacin FDA Label
• [4] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
• [5] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [6] Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
• [7] Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.